ArticleEuropean journal of nuclear medicine and molecular imaging2021
Why bother with alpha particles?
Article in European journal of nuclear medicine and molecular imaging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Emergence of a barium metal-organic framework for mitigating off-target effects of alpha radionuclide therapy.Theranostics · 2026Article
- Dosimetric evaluation of unlaminated radiochromic films exposed to an Americium-241 source using measurements and Monte Carlo simulations.Medical physics · 2025Article
- NeoadjuvantCancers · 2025Review
- Targeting CXCR4 with 212Pb/203Pb-Pentixather Significantly Increases Overall Survival in Small Cell Lung Cancer.Radiation research · 2025Article
- The untapped potential of dosomics for theranostics: shaping the future of personalized medicine.European journal of nuclear medicine and molecular imaging · 2025Article
- Targeting Glypican-3 in Liver Cancer: Groundbreaking Preclinical and Clinical Insights.Biomedicines · 2025Review
- It's a match: use of the radionuclide theranostic pairEJNMMI radiopharmacy and chemistry · 2025Article
- Preclinical safety and effectiveness of a long-acting somatostatin analogue [European journal of nuclear medicine and molecular imaging · 2025Article
- Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025Review
- PARP-Targeted Radiotheranostics with Auger Electrons: An Updated Overview.Current issues in molecular biology · 2024Review
- Biodistribution Assessment of a NovelLife (Basel, Switzerland) · 2024Article
- Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics.Theranostics · 2024Article
- DNA Damage by Radiopharmaceuticals and Mechanisms of Cellular Repair.Pharmaceutics · 2023Review
- Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal Carcinoma.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Covalent Proteins as Targeted Radionuclide Therapies Enhance Antitumor Effects.ACS central science · 2023Article
- Evaluation of Astatine-211-Labeled Fibroblast Activation Protein Inhibitor (FAPI): Comparison of Different Linkers with Polyethylene Glycol and Piperazine.International journal of molecular sciences · 2023Article
- Article
- Radiopharmaceuticals heat anti-tumor immunity.Theranostics · 2023Review
- Radiation safety considerations for the use of radium-224-calciumcarbonate-microparticles in patients with peritoneal metastasis.Frontiers in medicine · 2023Article
- Novel radionuclide therapy combinations in prostate cancer.Therapeutic advances in medical oncology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The approval of
Indexed as
Identifiers
34175980What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.